Our aim was to identify and quantitate cholesterol pools and transport pathways in blood and liver. By studying bile fistula subjects, using several types of isotopic preparations, simultaneous labeling of separate cholesterol pools and sampling all components of blood and bile at frequent intervals, we developed a comprehensive multicompartmental model for cholesterol within the rapidly miscible pool. Data in six components (bile acids, esterified cholesterol in whole plasma, and free cholesterol in blood cells, bile, a lipoproteins, and ,B lipoproteins) were modeled simultaneously with the SAAM program. The analysis revealed extensive exchange of free cholesterol between HDL and liver, blood cells, and other tissues. There was net free cholesterol transport from HDL to the liver in most subjects. The major organ that removed esterified cholesterol from blood was the liver. A large portion (4,211 gmol) of total hepatic cholesterol comprised a pool that turned over rapidly (t1/2 of 72 min) by exchanging mainly with plasma HDL and was the major source of bile acids and biliary cholesterol. Only 6% of hepatic newly synthesized cholesterol was used directly for bile acid synthesis: the analysis showed that 94% of newly synthesized cholesterol was partitioned into the large hepatic pool (putative plasma membrane free cholesterol) which exchanged rapidly with plasma lipoproteins. Bile acid synthetic rate correlated directly with the size of the large hepatic pool. In conclusion, hepatic and blood cholesterol pools and transports have been quantitated. HDL plays a central role in free cholesterol exchange/transport between all tissues and plasma. In humans, the metabolically active pool comprises a large portion of total hepatic cholesterol that, in part, regulates bile acid synthesis. (J. Clin. Invest. 1993. 91:923-938.) 
Introduction
Our aim was to identify and quantitate cholesterol pools and transport pathways in blood and liver. By studying bile fistula subjects, using several types of isotopic preparations, simultaneous labeling of separate cholesterol pools and sampling all components of blood and bile at frequent intervals, we developed a comprehensive multicompartmental model for cholesterol within the rapidly miscible pool. Data in six components (bile acids, esterified cholesterol in whole plasma, and free cholesterol in blood cells, bile, a lipoproteins, and ,B lipoproteins) were modeled simultaneously with the SAAM program. The analysis revealed extensive exchange of free cholesterol between HDL and liver, blood cells, and other tissues. There was net free cholesterol transport from HDL to the liver in most subjects. The major organ that removed esterified cholesterol from blood was the liver. A large portion (4,211 gmol) of total hepatic cholesterol comprised a pool that turned over rapidly (t1/2 of 72 min) by exchanging mainly with plasma HDL and was the major source of bile acids and biliary cholesterol. Only 6% of hepatic newly synthesized cholesterol was used directly for bile acid synthesis: the analysis showed that 94% of newly synthesized cholesterol was partitioned into the large hepatic pool (putative plasma membrane free cholesterol) which exchanged rapidly with plasma lipoproteins. Bile acid synthetic rate correlated directly with the size of the large hepatic pool. In conclusion, hepatic and blood cholesterol pools and transports have been quantitated. HDL plays a central role in free cholesterol exchange/transport between all tissues and plasma. In humans, the metabolically active pool comprises a large portion of total hepatic cholesterol that, in part, regulates bile acid synthesis. (J. Clin. Invest. 1993. 91:923-938.) Key words: high density lipoprotein * blood cell cholesterol * esterified cholesterol * multicompartmental analysis * hepatic cholesterol Free (unesterified) cholesterol (FC)' is ubiquitous in human blood and tissues; especially enriched in FC are plasma membrane bilayers and lipoprotein surface monolayers. In blood and in some tissues, FC transport is very dynamic and can occur by diverse mechanisms involving lipoproteins, lipoprotein receptors, transfer/binding proteins, flip-flop, lateral membrane diffusion, aqueous diffusion, and micelles, among others. To add to the complexity, FC can be converted reversibly to esterified form (the major form ofcholesterol in lipoproteins) and irreversibly to steroid hormones and bile acids. Cholesterol is the principal ingredient in two common disorders: atherosclerosis and gallstones.
The identification and magnitude of cholesterol transport pathways in the living whole organism are largely unknown. Hellman, Gould, Field, and Kurland were among the first to carry out in vivo studies in humans of cholesterol kinetics (1) (2) (3) (4) ; Goodman, Noble, and Dell identified a rapidly miscible pool (cholesterol in blood, liver, intestine, and a few other organs) that exchanged slowly with two large side pools (5) . Little is known about cholesterol transport between lipoproteins and specific tissues that comprise the rapidly miscible pool. In previous kinetic experiments in humans using isotopic mevalonic acid and isotopic FC in HDL or LDL, it was determined that plasma FC, probably in HDL, exchanged extensively with hepatic precursor compartments for biliary cholesterol secretion and bile acid synthesis, thus providing most of the substrate for these excretory pathways (6, 7) . Also, there was rapid exchange of FC between HDL and A lipoproteins (7) . These experiments lacked the data to provide sensitivity for measurement of (a) cholesterol transport between ( lipoproteins, liver, and other tissues, (b) unidirectional (net) FC transport to or from HDL over and above the exchange between HDL, liver, and other tissues, and (c) accurate tissue pool sizes since their estimates had wide limits. Based on insight gained from the previous experiments, the shortcomings were overcome by administration of multiple isotopes and then, in most current experiments, by separating HDL from ( lipoproteins immediately after collection of blood samples, analyzing blood cell cholesterol, collecting bile for analysis of cholesterol and bile acids, and analysis of plasma esterified cholesterol. These improvements in design allowed the acceptance of our hypothesis of net FC transport from HDL to a single precursor pool for both bile acid synthesis and biliary cholesterol secretion, and permitted quantitation of the size of this hepatic pool; we found that the latter varied in direct relation to the rate of bile acid synthesis. Furthermore, this series of studies provided additional evidence that HDL FC is the major pool of plasma cholesterol in direct communication with hepatic and extrahepatic tissue cholesterol pools.
Methods
Subjects. Nine experiments were carried out in five ambulatory volunteers with bile fistula at the Clinical Research Center, Medical College of Virginia; clinical information on these subjects is summarized in Tables I and II. Informed consent was obtained from each volunteer. They all had normal renal and liver function tests, a normal lipoprotein pattern on agarose gel, and excellent nutritional status: The range of body weight was < 1 kg in the 10 d preceding, during, and several days after all studies.
Four subjects were studied twice. In three subjects (I.D., E.B., and J.T.), the second experiment was started 1-3 d after the start ofthe first experiment. In subject R.T, the second experiment started 5 wk after the start of the first. For at least 2 d before and during all nine experiments, bile was continuously collected by gravity siphonage from a Tor U-tube which was monitored every 15-60 min to assure complete collection by preventing blockage of the tube. Under these conditions, the bile fistula seemed to be complete throughout the experiment as evidenced by: (a) acholic stools; (b) constant bile lipid secretion from hour to hour; and (c) the absence of 20 bile acids. Furthermore, in subjects I.D. and J.T., bile acids were not present in duodenal aspirates collected for 90 min the day before the first experiment.
Each subject was administered two labeled compounds (Table II) simultaneously by vein at about 11 a.m. over a 1-min period. The subjects fasted, except for water, for 12 h before and 6 h after administration of the labeled compounds. Blood samples, 4-7 ml each, were obtained at frequent intervals as shown in Figs. 1-3 and Table III . After the initial 6 h, blood samples were obtained after at least 3 h of fasting.
All raw data from six previously published experiments were reanalyzed under the constraint of the knowledge (kinetic information) gained from the nine new experiments. The clinical information and methods used in these six experiments have been published (6) .
Radiolabels. The DL[5-3H] mevalonic acid (dibenzylethylenediamine [DBED] salt), [1 ,2-3H]cholesterol, and [4-'4C]cholesterol were obtained from NEN Research Products, Boston, MA, and stored at -1 5'C in ethanol. Radiolabeled cholesterol was checked for purity by silicic acid column chromatography (8), thin layer chromatography (7) , and recovery of radioactivity as cholesterol digitonide (9) . The labeled cholesterol was not used if purity was < 94% by any ofthe three methods. Mevalonic acid was liberated from the DBED salt by the addition of 8.4% sodium bicarbonate and DBED was then extracted with diethyl ether. The aqueous solution was neutralized with HCl, diluted to a volume of 10 ml with sterile saline, passed through a 0.22-,um filter, assayed for radioactivity, and administered to subject E.H.I.
Cholesterol-labeled lipoproteins and albumin. Preparation of each labeled lipoprotein was carried out from a fasting sample of the subjects' blood obtained 1-3 d before the start of the experiment. The blood was collected in EDTA (1 mg/ml), immediately cooled to 5°C, and the blood cells removed at 2,700 rpm in a refrigerated centrifuge. Several 5-mm disks of filter paper (No. 1; Whatman Inc., Clifton, NJ) were placed in the bottom of sterile screw-top vials and impregnated under N2 with [4-`4C]cholesterol or [1,2-3H] cholesterol in 100 uI ethanol which was quickly evaporated by the gentle stream of N2. The subjects' fresh plasma (20-30 ml at 5C) was immediately added and the vial was gently agitated in a 5°C water bath for 2 h. Approximately 10-20% of the radioactivity applied to the filter paper disks was recovered in the plasma. Normal serum albumin (human, 25%, USP; Cutter Laboratories, Inc., Berkeley, CA, diluted to 12.5% with sterile 0.15 M NaCl) was coupled, by exchange, with [4-'4CJcholesterol for administration to J.T.; 15 ml of 12.5% albumin was added to '4C-cholesterol impregnated filter paper disks under N2, as above. The '4C-cholesterol-albumin solution was decanted after 3 h and administered to the subject (J.T.I and J.T.II, Table II ) after passage through two 0.22-jtm filters connected in series. In subject E.H.I, [4-'4C]cholesterol was administered in particulate form with albumin. The '4C-cholesterol in 0.07 ml of absolute ethanol was slowly added to 15 ml ofhuman albumin (Cutter Laboratories, Inc.) with gentle mixing and administered within 2 h without filtration.
An aliquot ofeach lipoprotein preparation containing isotopic cholesterol was obtained immediately before administration to the subject. Analysis revealed a lipid composition identical to that of the corresponding native lipoprotein. Between 95 and 100% ofthe isotopic cho- (Table II) ; 0.0-0.3% (mean 0.18%) of the 3Hor '4C-cholesterol was esterified in the VLDL and LDL preparations (data not shown); 0.9-4.5% (mean = 1.9%) was esterified in the HDL preparations. In the preparations of albumin containing '4C-cholesterol (E.H. and J.T.), 100% of the '4C-activity was unesterified. Each preparation of LDL or VLDL migrated as a single band on agarose gel electrophoresis (10) and paralleled the corresponding lipoprotein standard. There was a relatively faint pre-Beta band in each HDL preparation. Treatment of HDL preparations with heparin-MnCl2 before electrophoresis completely eliminated this pre-Beta band, presumably Lp(a), but did not change HDL migration. Agarose gels (2 mm thick) were also sliced and assayed for radioactivity. For LDL and VLDL preparations, > 90% of the radioactivity in the gel was associated with the appropriate lipoprotein fraction; remaining radioactivity was spread over the entire gel. In HDL preparations, 4-5% ofthe radioactivity was concentrated in the pre-Beta band and 84-89% in HDL; the remainder was evenly distributed throughout the gel. Furthermore, > 85% of the radioactivity floated in the appropriate density range when an aliquot of each labeled lipoprotein preparation was reultracentrifuged.
Analyticprocedures. Some blood samples were collected in heparinized (143 USP U) tubes and were immediately centrifuged at 3,000 rpm at 5°C for 5 min to separate plasma from cells. The plasma was immediately treated with heparin-MnCI2 to precipitate the ( lipoproteins (11) . After centrifugation for 5 min, the supernate (containing a-HDL) was decanted into chloroform:methanol. The precipitate was resuspended and washed twice to remove all traces of a-HDL. The isolated a and ,B fractions were periodically monitored by agarose gel electrophoresis and always found to be free of contamination. In E.H., E.B., and I.D., most blood samples were collected on EDTA, 1 mg/ml, 5°C; after rapid separation of blood cells, the whole plasma was added to chloroform:methanol without separation of lipoproteins; in J.T., R.T.I, and R.T.II, only one to two whole plasma samples were analyzed without separation oflipoproteins. Blood cells were washed three times with twofold volume of 0.15 M NaCl (5°C). Throughout all procedures described above the samples were maintained at 5°C and processed quickly to retard exvivo lipid exchange and esterification. Immediately after isolation, the whole plasma, a lipoprotein, f3 lipoprotein, blood cell, and bile samples were added to 20 vol of chloroform:methanol (2: 1, vol:vol).
Chloroform and methanol phases were separated by the addition of one-fifth volume ofwater (12) . The chloroform phase was subjected to silicic acid column chromatography to separate free from esterified cholesterol (8) . Free cholesterol mass was determined by gas liquid chromatography using coprostanol as the internal standard. The stationary phase was 3% SP-2401 (Supelco, Inc., Bellefonte, PA). Carrierfree cholesterol was added to an aliquot ofthe free cholesterol fraction; the digitonide was formed, dissolved in methanol, and assayed for 3H and 14C activity by liquid scintillation counting (1217 Rackbeta; LKB Instruments, Inc., Gaithersburg, MD). The external standard method was used for quench correction; each sample was counted for 20 min. Esterified cholesterol was hydrolyzed with 5% KOH for I h, neutralized with HC1, and the liberated free cholesterol precipitated as the digitonide; mass was determined colorimetrically on an aliquot ofthe digitonide (9); another aliquot was dissolved in methanol and assayed for 3H and 14C activity. The esterified cholesterol in a and # lipoprotein fractions (isolated in J.T. and R.T.) were pooled for the analysis so that all esterified cholesterol data represents whole plasma.
Determination of masses ofindividual bile acids by gas chromatography and of radioactivity in cholic acid and in chenodeoxycholic acid were carried out on the methanol phase of the original chloroform:methanol extract ofbile, as described previously (6) . Procedural loss of each bile acid species was estimated using taurineand glycine-conjugated bile acid standards and the final calculations corrected accordingly. Loss ofcholic and chenodeoxycholic acids averaged 15% (range 8-21%). DL[5-3H]mevalonic acid was given to E.H.I. Bile acid radioactivities in E.H.I were corrected for loss of 3H: (a) during the conversion of cholesterol to bile acids and (b) attributable to the analytic procedure as described previously (6) .
Results
Blood cholesterol concentrations and bile lipid secretion rates.
The blood cholesterol concentrations are shown in Table I . In excess of 99.0% of cholesterol in blood cells was free (unesterified). Blood cell FC content is expressed as ,umol/ 100 ml plasma and was calculated from the hematocrit and lsmol FC per ml packed blood cells. In I.D. and E.B., whole plasma FC concentration (not shown) was essentially identical to the sum 926 C. C. Schwartz, L. A. Zech, J. M. VandenBroek, and P. S. Cooper of a-FC plus fl-FC. In no subject did the cholesterol concentration ofany component ofblood change during the experiment. Likewise, the biliary cholesterol and bile acid secretion rates were constant in each subject as reflected by the small statistical variance (Table I) .
Specific activity data. The specific activities of whole plasma FC, plasma esterified cholesterol (EC), biliary cholesterol, and cholic acid in subject E.H.I are shown in Fig. 1 . Blood cell radioactivity was not measured. Chenodeoxycholic acid 3H and '4C specific activities are not shown in E.H.I or in the other subjects since they were virtually identical to cholic acid at all times as noted previously in bile fistula subjects ( 13) .
After [3H]mevalonic acid administration to E.H.I (upper panel of Fig. 1 ) there were at least 15 min before appearance of radioactivity in all samples. The delay was -4 min longer for cholic acid than for biliary cholesterol. After the delay period the rate ofbuild-up ofradioactivity was most rapid in bile acids followed by biliary cholesterol, plasma FC, and then plasma EC. The peak specific activity was highest and earliest in the bile acids. Bile acid and biliary cholesterol specific activities became similar after 400 min; however, after 600 min, bile acid specific activity had crossed over the biliary cholesterol specific activity and remained slightly lower than biliary cholesterol. 20,000 -, , , Both bile acid and biliary cholesterol merged with plasma FC within 800 min, after which plasma FC and biliary cholesterol specific activities were essentially identical through 8,775 min. The plasma EC specific activity followed that ofplasma FC in a classic product-precursor fashion, respectively. The cholic acid and cholesterol specific activities after particulate '4C-FC administration to E.H.I are shown in the lower panel of Fig. 1 . As opposed to the 25-min delay before 3H appearance in biliary cholesterol of E.H.I, the delay for "`C activity was -15 min and was similar for biliary cholesterol and bile acids. Bile acid "'C specific activity was the same or slightly lower than that of biliary cholesterol throughout the 8,775 min. The relatively constant plasma FC specific activity from 150 to 500 min reflects the particulate form of a large portion ofthe administered "'C-FC; immediately after administration, a large portion of the "'C-FC tracer is taken up by the reticuloendothelial system and most is gradually released into plasma during the subsequent 10 h (14). This "particulate" form of 14C-FC tracer is consistent with the model as shown below.
In a previous publication regarding subjects administered isotopic FC-albumin in particulate form, we reported that plasma FC specific activities were higher than specific activities of biliary cholesterol and bile acids throughout the experiment ternal standard for gas chromatography in those experiments (6) . After isotopic mevalonic acid administration, as we also and we subsequently found that there is a minor sterol present reported, plasma FC specific activities were higher than the bile in plasma with the same retention time. This resulted in 12components after 750 min. Sa-cholestane was used as the in-17% underestimation of plasma cholesterol mass and overesti- mation of specific activity. When corrected, the plasma FC specific activities in the previous publication were essentially identical to biliary cholesterol specific activities at all times after the initial period of equilibration as also observed in the new subject, E.H.I (Fig. 1 ). (Fig. 2 , upper-I and lower-II) there was a precipitous decline in a-FC specific activity. The f-FC specific activity rapidly increased and reached that of the a-FC by 30 min. Beyond 30 min, (-FC specific activity was slightly higher than a-FC. After administration of isotopic FC in LDL (Fig. 2 , upper-II and lower-I) there was a gradual decline in f-FC specific activity. The a-FC specific activity rapidly increased but the peak was low and did not intersect the f3-FC. These a-FC and 3-FC specific activity relationships are identical to those observed previously (7) . Whole plasma FC specific activities were nearly identical to 3-FC after the initial 30 min of each experiment reflecting the high proportion that 3-FC mass contributes to whole plasma FC mass (Table I) .
Biliary cholesterol and bile acid specific activities increased rapidly after an initial delay of 10-20 min after administration of isotopic FC in HDL and LDL (Fig. 2) . Bile acid specific activities were lower than biliary cholesterol during the initial incline suggesting a longer delay for bile acids. The peak biliary cholesterol and peak bile acid specific activities were reached 90-140 min after administration of labeled compounds. From 100 to 500 min there was a trend for bile acid specific activity to be slightly higher than biliary cholesterol and then slightly lower for the remainder ofthe experiment. Bile acid and biliary cholesterol specific activities increased more rapidly and reached a peak sooner after administration of isotopic FC in HDL than in LDL; this was observed previously ( 15) .
Shown in Figs. 2 and 3 for the first time in humans are composite specific activities including bile acids and cholesterol in all major components of blood and bile. The peak specific activity of biliary cholesterol and bile acid was always less than that of plasma FC at the corresponding time. Plasma FC and biliary cholesterol specific activities merged after the initial 100-200 min, and thereafter remained nearly identical. Blood cell FC specific activity tended to increase more rapidly after administration ofisotopic FC in HDL than in LDL. Equilibration of blood cell FC and plasma FC specific activities was reached by 400-600 min corresponding to the time when blood cell FC specific activity reached a peak. This suggests a precursor (plasma FC)-product (blood cell FC) relationship.
The specific activity of EC in plasma increased at a relatively slow rate for the initial 200 min; then, either the rate of incline diminished considerably or the specific activity plateaued until it intersected plasma FC after -1,500 min. The specific activities intersected at the plasma EC peak. J.T. was first administered 3H-FC in VLDL/LDL (d < 1.062) followed 25 h later by a second experiment in which HDL-3H-FC was administered. The 3H specific activity versus time patterns and interrelationships, shown in Fig. 3 (upper panel), were the same as those seen in I.D. and E.B. given the corresponding labeled lipoproteins (VLDL/LDL considered equivalent to LDL). min-'+FSD I.D. 0.00143±8% 0.00015±9% 0.00364±92% 0.0330±21% 0.00408±62% 0.0019±36% 0.00185 0.0147±16% 0.00020 0.0004±107% E.B. 0.00105±5% 0.00010±5% 0.00544±35% 0.0293±11% 0.00125±109% 0.0029±17% 0.00185 0.0156±11% 0.00053 0.0014±29% J.T. 0.00091±11% 0.00040±11% 0.00517±35% 0.0316±16% 0.00483±36% 0.0028±22% 0.00208 0.0243±10%7o 0.00016 0.0003±88% R.T.I 0.00156±16% 0.00029±16% 0.00532±43% 0.0770±34% 0.00536±40% 0.0007±310% 0.00087 0.0105±61% 0.00112 0.0028±26% R.T.II 0.00120±15% 0.00018±15% 0.00161±81% 0.0387±18% 0.00600±18% 0.0011±48% 0.00120 0.0177±12% 0.00092 0 0026±12%
In these subjects not administered labeled mevalonic acid, L(1 1, 23), L(13, 1), L(12, 1), t11 and tl3 could not be measured. L(13, 1) and L(12, 1) were fixed at 0.0535 and 0.9465, respectively, calculated from the mean of corresponding values in Table VII normalized To avoid problems associated with use ofalbumin containing ['4C]cholesterol in particulate form (6, 14) and to determine if albumin could be used to administer tracer-FC into blood in a more physiologic manner, J.T. was given albumin coupled by exchange with '4C-FC at the same times he was 6.15
given the 3H-FC compounds. The observed '4C specific activities are shown in Fig. 3 (lower panels) . Qualitatively, the '4C t7;tl0 min-'+FSD min 0.1288±19% 0.0368±14% 0.0084±14% 0.00024±15% 0.0053±6% 0.00031±31% 0.00019±40% 0.00027±33% 0.142±11% 10 0.0941±11% 0.0290±11% 0.0096±5% 0.00026±6% 0.0058±5% 0.00055±27% 0.00001±550% 0.00008±41% 0.092±9% 18 0.1203±7% 0.0224±8% 0.0153±11% 0.00045±27% 0.0060±4% 0.00021±56% 0.00017±67% 0.00010±98% 0.100±14% 10 0.0382±76% 0.0165±19% 0.0252±25% 0.00080±96% 0.0069±5% 0.00059±82% 0.00001±400% 0.00161±79% 0.038±9% 21 0.0547±10% 0.0164±9% 0.0084±52% 0.00015±263% 0.0070±15% 0.00003±295% 0.00046±37% 0.00163±103% 0.066±11% 28 and the 3H activities in J.T. II (given HDL-3H-FC) were nearly identical within each component at all times when expressed as fraction of dose. Subject R.T.I was simultaneously administered VLDL-3H-FC and LDL-'4C-FC to rigorously test the following observa-tions. In a previous study, a subject was also simultaneously administered VLDL-3H-FC and LDL-14C-FC but data collection was limited to a and d lipoprotein samples (reference 7, subject 3). In this previous study, the fraction of 3H-FC dose observed in a-FC was virtually identical to the fraction of 14C- (L(m,n) ). Compartments 23, 11, 24, and 25 represent isotope (tracer) only and contain no mass. C(23) and C(24) contain the total amount of injected tracers of L-MVA and FC, respectively. C( 11) is a delay for incorporation of isotopic MVA into NSC. C( 25) is particulate isotopic FC and L(25,24) represents the percent of injected isotopic FC in particulate form since L(24,24) was forced to equal 100 min-'. See text for discussion of isotopic FC in particulate form. Other symbols described in Fig. 4 legend.
Cholesterol Transport in Bile Fistula Subjects 931 FC dose in a-FC at each time. In addition, the fractions of 3H dose in 3-FC and of '4C dose in f3-FC were essentially identical.
These observations suggested similarity ofmetabolism ofFC in VLDL and LDL. For the new study in R.T.I, all components of blood and bile were isolated to search more rigorously for differences in LDL-and VLDL-FC metabolism. The 3H and 14C specific activities, expressed as fraction of dose per micromole, are shown in Table III . A difference between the fraction of 3H dose and of 14C dose within each component was tested for statistical significance using a nonparametric sign test. A chi square value of6.75 was obtained for the difference between 3H dose and 14C dose in biliary cholesterol, significant at the 0.05 level for an average difference ofonly -0.002. This is ofdoubtful physiologic significance especially since a difference between fraction of 3H dose and of "4C dose in each of the other five components did not approach statistical significance. The results strongly support similarity of metabolism of the FC in VLDL and LDL. Also, VLDL-FC and LDL-FC can be com- (8)) and blood cells (M(3)) were determined from the observed plasma concentrations (Table I) and estimated plasma volume as 4.5% of kg body weight. During the modeling and iterative processes, the observed values for: (a) plasma and blood cell pool sizes and (b) biliary cholesterol and bile acid secretion rates were tightly constrained to stay within 5% of the experimentally observed values shown in Table I.
The only significant outputs of cholesterol from the body are via bile acid synthesis and biliary cholesterol secretion. Since each of these bile fistula subjects appeared to be in a steady state during the relatively brief experiments, the total cholesterol input (U1) in each subject was fixed at the sum of observed rates of bile acid secretion plus biliary cholesterol secretion.
The model was constrained by the simultaneous consideration of 3H and 14C specific activity data in each subject. This imposed rigid constraints on the topology of the model and narrowed the confidence limits on the final parameter values since the same kinetic parameters were required to fit both 3H and 14C radioactivity data obtained after administration of tracers in separate cholesterol pools. The multilabel (mevalonic acid, VLDL-FC, HDL-FC, and LDL-FC) approach afforded the opportunity to construct a model based on the transport oftracers between compartments that was consistent with the number of exponentials in the specific activity response of (Table I) all observed compartments and could predict the specific activity response in the compartments where observations were not possible. In E.H.I, a and (3lipoproteins were not isolated and tracers were not specifically injected into either a-FC or 13-FC compartments. Therefore, a modified model was used as shown in Fig. 5 in which there is a single whole plasma FC compartment, C(45). The primary model shown in Fig. 4 was used in experiments during which a and f3 lipoprotein samples were isolated (I.D., E.B., J.T., and R.T.). The sum of C(4) and C(5), represented by C(45), was used to fit the whole plasma FC data also obtained. Regarding I.D. and E.B., although most of the observed FC data from plasma consisted of whole plasma FC specific activities, this approach allowed good identification and estimation of the parameters of C( 4) and C(S) because: (a) labeled compounds were injected into C( 4) and C(S) and (b) three to four a and f3 lipoprotein samples, obtained within 90 min of administration of the labeled compounds, were sufficient to identify these parameters.
In I.D., E.B., and J.T., a second experiment (II) was carried out 1-3 d after the start of the first experiment (I). Because experiments I and II were at the same steady state, all data from experiment I including labeled material and all data from experiment II were combined with the second set of initial conditions introduced at the appropriate time and fit simultaneously. This allowed labeled material from experiment I to remain in the system during the fit of experiment II to obtain one final set of parameter solutions. In support of a steady state in I.D., E.B., and J.T., the bile fistula remained patent, bile flow was constant, and bile lipid secretion rates and blood cholesterol concentrations were unchanged from the start of experiment I through the end of experiment II. In contrast, R.T.I and R.T.II were fit separately since they were studied 35 d apart at markedly different steady states with regard to bile acid synthesis and biliary cholesterol secretion (Table I) .
Development ofthe model. The final model is shown in Fig.  4 . Except for the mevalonate portion, the model contains the minimal structure necessary to fit the data in I.D., E.B., J.T., and R.T., who were administered isotopic FC in lipoproteins along with a small amount of isotopic EC. The pathways designated by the thin dashed-lines, C(23), C( 1), delay 1 1, and delay 13 are defined when isotopic mevalonic acid is administered. VLDL-FC and LDL-FC were modeled separately in the antecedent to this model (7) . They are now combined in C(S) for reasons presented above and discussed previously (7) .
The FC in blood cells (C( 3) , not in prior models) was assumed to exchange bidirectionally with FC in (3-VLDL/LDL and in a-HDL, compartments 5 and 4, respectively. The assumption of exchange without net transport means that L(4, 3) and L(3, 4) were interdependent as were L(5, 3) and L(3, 5) since M(3), M(4), and M(5) were tightly constrained observations; therefore, L( 3, 4) and L( 3, 5) were adjustable and L(4, 3) and L( 5, 3) were dependent during the iterative process. Transport (not only bidirectional exchange) of FC between a-HDL and a rapidly turning over tissue pool (C( 12), probably hepatic) was found previously (7) . In the current model FC transport between C( 12) and (3-VLDL/LDL lipoproteins has been added since it improved the fit of several compartments, primarily of bile acids and biliary cholesterol.
a-HDL-FC was the source of plasma EC, C( 8), formed de novo in the model in Fig. 4 . This pathway was based on previous modeling and a considerable body of data from other laboratories showing that HDL-FC and lecithin-cholesterol acyltransferase are the source of most plasma EC in man ( 16, 17) . An EC exchange compartment, C( 18), was used to fit the slow change in specific activity of plasma EC after 300 min (Figs. 1-3 ). We found that M( 18) was -60% ofM(8) while modeling experiments with a duration of at least 2 d. Other investigators have found that extravascular ApoB, ApoA,, and ApoA2 pools are -60% of the vascular poo1 sizes ( 18, 19) . Therefore, we assumed C ( 18) is extravascular lipoprotein EC and have constrained M( 18) to be 60% of M (8) . Thus, L(8, 18) and L( 18, 8) are interdependent; L( 18, 8) was allowed to adjust, and L(8, 18) was fixed equal to L( 18, 8) X 1.667. The output of plasma EC was assumed to occur from C (8) to the tissue pools, C( 12) and C(6), and both L( 12, 8) and L(6, 8) were freely adjustable.
The bile acid and biliary cholesterol precursor pools and related transport pathways shown in Fig. 4 are simplified as compared with our previous report in which separate precursor pools were used (6) . There were two reasons for the simplification. First, except for the longer delay before appearance of radioactivity in bile acids, the bile acid specific activities and biliary cholesterol specific activities were similar after administration of isotopic cholesterol to bile fistula subjects. Bile acid and biliary cholesterol specific activities were also similar starting 300 min after isotopic MVA administration. These similarities have occurred in every bile fistula subject suggesting a common precursor pooi for biliary cholesterol and most newly synthesized bile acids. The marked difference between bile acid and biliary cholesterol specific activities during the period from 20 to 300 min (Fig. 1, upper panel) after isotopic mnevalonic acid administration is addressed below. Second, examination of rate constants for separate bile acid and biliary cholesterol min-'+FSD E.H.I 0.37±3% 0.00017±11% 0.012±9% 0.0006±6% 0.00014±6% 0.0104±6% 0.0115±4% 0.0093±8% 0.0023±8% G.P. 0.36±32% 0.00086±19% 0.033±17% 0.0010±30% 0.00043±30% 0.0094±13% 0.0140±18% 0.0098±33% 0.0049±33% P.C. 0.42±6% 0.00212±6% 0.015±5% 0.0008±4% 0.00016±5% 0.0093±7% 0.0298±7% 0.0049±72% 0.0018±63% L.C. 0.49±16% 0.00063±13% 0.027±9% 0.0013±10% 0.00017±10% 0.0081±7% 0.0150±10% 0.0140±15% 0.0052±16% T.T. 0.40±5% 0.00042±16% 0.022±9% 0.0009±4% 0.00032±4% 0.0066±5% 0.0078±5% 0.0095±8% 0.0028±8% I.H. 0.35±18% 0.00603±34% 0.075±24% 0.0010±10% 0.00025±11% 0.0056±7% 0.0061±9% 0.0070±20% 0.0031±19% G.A.I 0.36±13% 0.00372±18% 0.036±16% 0.0013±5% 0.00032±5% 0.0066±7% 0.0091±6% 0.0101±12% 0.0040±13% precursor pools, called C( 2) and C( 3), respectively, in the previous report, revealed they were nearly identical ( Table V in  reference 6 ). Therefore, we propose the simplified model ( Fig.  4 ) containing a common precursor pool, C( 12), for bile acid synthesis and biliary cholesterol secretion. We have retained pathways from the previous model for newly synthesized cholesterol (NSC) transport directly into bile acids, now called L( 13, 1 ) . This direct input of NSC accounts for the difference between bile acid and biliary cholesterol specific activities seen between 20 and 300 min after isotopic mevalonic acid administration.
The delayed appearance of radioactivity in biliary cholesterol was due to transit time through the biliary tract, delay 10 in Fig. 4 . An identical portion of the time delay for bile acids was fixed to equal the delay for biliary cholesterol ( t7 = tlo). An additional delay-like feature was necessary for bile acids and the time required for passage through C( 16) was used. C ( 16) probably represents intermediates in the bile acid synthetic pathway.
The model shown in Fig. 5 was modified from Fig. 4 and used to analyze the data in E.H.I and six subjects previously studied with isotopic FC in particulate form and isotopic mevalonic acid (6) . Since a comprehensive model was not developed then, forcing functions had been used to simulate the plasma FC and EC specific activities and the information obtained from the 6 prior experiments was of limited scope (6) . For the present analysis, M(3) was estimated for the six old studies from hematocrit and plasma volume and from mean blood cell FC concentration ofthe new studies in this report. Radioactivity was not measured in the blood cells of E.H.I but mass was measured in three samples (Table I ). M(3) was loosely constrained (±30%) to the estimated value during analysis of all seven experiments with the modified model in Fig. 5 . In the modified model, Fig. 5 , C(24) represents total injected tracer FC ofwhich a major portion is in particulate form. L (24, 24) was fixed at 100.0 min-' to instantaneously distribute the injected tracer. L(45, 24) was dependent (L(45, 24) = 100-L (25, 24) ) and L(25, 24) was adjustable. Thus, all tracer injected into C(24) was instantly partitioned between C(25), particulate tracer FC, and C(45), plasma FC.
E.H.I was administered [3HJmevalonic acid simultaneously with the particulate 14C-FC. In Fig. 5 , the mevalonate tracer pool (C(23)), delay 11, and NSC (C(1)) are adopted from previous publications (6, 7) . Delay 13 is new and was necessary to postpone appearance ofradioactivity from NSC in secreted bile acids.
Model parameter solutions. The rate constants (L(m,n)) and delay times (tn) for subjects I.D., E.B., J.T., and R.T. are shown in Table IV . Rate constants among subjects varied to an extreme degree (more than sevenfold) only for pathways that had comparatively low values; for example, L(3, 5) and L(6, 8) varied over a wide range and had high fractional standard deviation (FSD) when compared to L (3, 4) and L(12, 8), respectively. As expected in brief experiments (< 1,000 min), the solutions for pathways from compartments with slow turnover were highly variable and poorly defined (high FSD) in subjects R.T.I and R.T.II; examples were L(4, 6), L ( 12, 8) , L(6, 8) , and L ( 18, 8) . The value of administering label into two compartments is shown in R.T.I in whom both labels were administered into C(5); L( 12, 5), L (3, 4) , and L(5, 4) varied widely from the other subjects and were poorly defined.
Transport rates (,gmol/min) for subjects I.D., E.B., J.T., and R.T. are shown in Table V . The high rate of FC transport between a-HDL and 13-VLDL/LDL (R(5, 4) and R(4, 5)) was expected (7) . A striking new result was the high rate of FC transport between a-HDL and the putative liver (C(12)), blood cell (C( 3)), and other tissue (C(6)) pools relative to the transport between ,B-VLDL/LDL and the same pools. This central role of HDL occurred even though the concentration of HDL FC was -25% of VLDL/LDL FC. There was net FC efflux to HDL from tissue C(6), the magnitude of which depended on the amount of plasma EC that entered C (6) . A portion of the FC transport between a-HDL and C( 12) was undoubtedly due to bidirectional exchange, but there was net FC transport of [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] ,gmol/min to C( 12) from HDL in four of five experiments. Transport ofplasma EC to C( 12) was greater than to C(6) in four of five experiments; in the exception (R.T.II), this difference was very poorly estimated because of the brief duration of the experiment.
Pool sizes in units of tumol are shown in Table VI . As expected, M(6) was the largest pool but in the brief experiments in R.T., M(6) varied from the values for I.D., E.B., and J.T., and was less well defined (high FSD). M( 12) was well defined even in briefexperiments because of its rapid turnover. M ( 12) was much larger than the mass of separate bile acid and biliary cholesterol precursor pools estimated with a previous model in which many FC transport pathways were not identified (6) . (7, 16) tll t13 tIo min 0.0030±5% 0.00014±5% 0.00129±4% 0.00056±4% 0.00006±250% 0.00203±33% 74±7% 0.00198±5% 0.220±300% 5 16 14 0.0053±81% 0.00098±69% 0.00154±9% 0.00023±290% 0.00053±130% 0.00130±62% 88±18% 0.00167±18% 0.040±20% 9 10 17 0.0095±23% 0.00095±36% 0.00213±8% 0.00093±8% 0.00009±200% 0.00200±52% 51±9% 0.00387±13% 0.044±7% 3 14 8 0.0064±26% 0.00058±22% 0.00178±6% 0.00061±24% 0.00005±200% 0.00020±51% 90±12% 0.00022±13% 0.074±14% 4 15 11 0.0012±22% 0.00010±9% 0.00285±7% 0.00078±9% 0.00018±53% 0.00096±38% 92±13% 0.00149±4% 0.051±14% 7 17 13 0.0012±57% 0.00008±44% 0.00172±8% 0.00079±29% 0.00001±200% 0.00180±45% -0.043±40% 5 15 20 0.0014±21% 0.00074±11% 0.00204±6% 0.00048±10% 0.00040±40% 0.00084±34% 0.039±27% 7 15 26 and for the six previous experiments reanalyzed with the new model in Fig. 5 . L ( 11, 23) is the fraction of tracer mevalonic acid converted to cholesterol; the range was 35-49%. L( 13, 1 ) and L( 12, 1) comprised a mean of 5.35 and 94.65%, respectively, of L( 1, 1 ). The mean L( 1, 1 ) was 0.0334 min'equivalent to a t112 of 21 min for NSC. Most of the rate constants in Table VII have either corresponding or equivalent counterparts in Table IV ; they are remarkably similar among all 12 experiments in spite of use of a variety of labeled compounds. Equivalent rate constants in Tables VII and IV (4, 6) .AsinTableIV,L (12, 8) was greater than L(6, 8) with a single exception, subject G.P. in whom the experiment lasted < 1,000 min. The solution for L (25, 24) shows that 51-92% ofthe FC tracer was administered in particulate form. Transport rates for subject E.H.I and the six reanalyzed experiments are shown in Table VIII . Compared with transports in Table V , the corresponding and equivalent transport rates in Table VIII are remarkably similar. FC was transported most rapidly between plasma and (in descending order) the liver (C( 12)), blood cells, and other tissues. Cholesterol ester synthesis, R (8, 4) Table IX . The NSC pool size, M( 1 ), was only -4% of the exchangeable hepatic FC pool, M ( 12) . The adjustable pool sizes were well defined (low FSD) with rare exception. M ( 12) , the size of the putative hepatocyte cholesterol pool available for bile acid synthesis was directly related to R(0, 7), the rate of bile acid synthesis. The relationship and regression analysis are shown in Fig. 6 , for which each subject's M (12) and R(0, 7) were normalized to a body weight of 70 kg. Sensitivity testing (20) revealed that the relationship was not due to dependence of M( 12) on U1, but to FC transport between C( 12) and plasma. Testing was done by changing U1 over a sixfold range with bile acid synthesis tightly constrained to the experimentally observed rate; M ( 12) changed < 10%.
Discussion
The model shown in Fig. 4 is the first in humans which has comprehensively identified and quantitated cholesterol trans-port between all major components of blood, several tissues, and bile. The pools and transports identified in these experiments, which ranged in duration from 8 h to 6 d in humans with chronic bile fistula, most likely represent cholesterol within the rapidly miscible pool characterized by Goodman and Samuel and their co-workers (5, 21 ) . In support, the sum of all pool sizes normalized to 70 kg body wt was 55,242 ptmol (21.4 g) , averaged from the 12 measurements in 11 bile fistula subjects. Samuel and Perl estimated a rapidly miscible pool size of 25.3 g in two normal subjects and Smith et al. estimated a pool of 25.9 g in eight normals with intact enterohepatic circulation (21, 22) .
The model shown in Fig. 4 and as modified in Fig. 5 identifies the major cholesterol compartments and transports in the liver. Since hepatocytes are the major site ofcholesterol synthesis in the whole animal, it was essential to define trafficking and/or sorting of hepatic NSC. Sorting has been difficult to is hepatic cholesterol that exchanges rapidly with plasma lipoproteins and also serves as precursor for biliary cholesterol and most newly synthesized bile acids. Shown are the data from all 13 bile fistula subjects studied to date by the investigators; 12 subjects (in) were described in this report and in part in reference 6, and 1 subject (S.W.; *) was studied with a different design using esterified 3H-and free '4C-cholesterol in HDL and analyzed using the model in Fig. 4 . The linear regression results±SE for the slope and y intercept are shown; t = 3.98, P < 0.005. The y intercept (0.90) was not significantly different from 0. Without S.W., y = 0.00096 (±.00029) x + 0.85 (±1.21); r = 0.73 (P < 0.01); t = 3.38, P < 0.01. * _ Y tHdD°s tudy because, unlike newly synthesized protein, NSC has neither an identifiable intracellular location nor a marker such as signal peptide or propiece. Parameters of NSC were quantitated using isotopes to simultaneously label two cholesterol pools: (a) preformed exchangeable cholesterol with isotopic FC introduced in blood and (b) NSC with isotopic mevalonic acid. With this design, the isotopic FC accurately defined the exchangeable cholesterol pool in the liver, C( 12), which then allowed accurate definition of size and rate constants of NSC (C( 1)) by the isotopic mevalonic acid. The t1,2 of NSC was 21 min and the average size of C( 1 ) was 219 Amol/70 kg. Thus, the pool of NSC represents < 3% of total hepatic free cholesterol assuming the latter value is -7,500 gmol (see below).
Using entirely different methods, Lange reported similar values: NSC constituted 1% offibroblast free cholesterol, had atl 2 of 10-60 min in fibroblasts, and had a t1/2 of 20-30 min in Leydig tumor cells (23) .
We found that < 6% ofnewly synthesized cholesterol molecules were used directly for bile acid synthesis and these passed through a 15-min delay; > 94% of NSC entered the exchangeable hepatic pool, C ( 12) , and most of this cholesterol entered plasma. The enzyme cholesterol 7a-hydroxylase is located in the endoplasmic reticulum. If the final step of cholesterol synthesis was also located in the endoplasmic reticulum, it might be anticipated that > 6% would be used by cholesterol 7a-hydroxylase in these subjects with maximally stimulated cholesterol and bile acid synthesis. Investigators have found that the final step in cholesterol synthesis occurs distant from endoplasmic reticulum, or that NSC is segregated in vesicles for transport to plasma membrane (24, 25) . Our data support the latter possibilities.
Our results in conjunction with those of other investigators suggest that most of C( 12) is located in hepatocytes of these bile fistula subjects. (a) A compartment with the size and rate constants of C( 12) was necessary to fit the plasma FC specific activity and mass data and to fit the biliary cholesterol, cholic acid, and chenodeoxycholic acid specific activity data. (b) The normal liver (1,500 g/70 kg adult) contains 5 ,umol FC/g wet wt or a total of 7,500 ,umol FC. Compartment 12 averaged 4,211 ,mol/70 kg, well within this upper limit of 7,500 ,gmol. The latter value includes FC in nonparenchymal cells. If nonparenchymal cell FC exchanged slowly with plasma and comprised part of C(6), then C( 12) could possibly comprise the vast majority of hepatocyte FC. This possibility is compatible with the findings of Johnson et al. in a hepatoma cell line; nearly 100% ofthe FC in Fu5AH cells was in rapid equilibrium with HDL in the media (26) .
Cholesterol is present in all membranes of the hepatocyte with the largest portion, -80%, in plasma membrane (27) . Bile acid synthesis starts from cholesterol in the endoplasmic reticulum. In light ofthe kinetics suggesting that C( 12), with a t,/2 of72 min, comprises the majority ofhepatocyte cholesterol and substrate for bile acid synthesis, there must be very rapid equilibration of FC between plasma membrane and certain interior membranes; the t112 for this equilibration between membranes must be < 15 min or the FC in interior membranes could have been detected by the kinetic analysis. Availability of FC specifically in endoplasmic reticulum is, therefore, not rate limiting for bile acid synthesis in the intact cell. The direct relationship with M( 12) (Fig. 6) interior membranes. It seems unlikely that C 16) represents microsomal FC available for bile acid synthesis since M( 16) was very small, had features of a delay, was all destined for bile acids, and was only weakly related to bile acid synthetic rate; C( 16) probably represents intermediates in the synthetic pathway.
We found a direct correlation between the bile acid precursor pool size, M( 12), and the rate of bile acid synthesis, R (0,7 ). The analysis shed some light on the mechanism ofthis interrelationship. The rate of bile acid synthesis is regulated by the amount and activity ofcholesterol 7a-hydroxylase and possibly by the amount of available cholesterol substrate (28) . In rats, regulation by availability of microsomal cholesterol substrate for 7a-hydroxylase has not been supported by Bjorkhem et al. who found excess substrate (29) . Regulation could be different in humans, or cholesterol in C( 12) could regulate the amount of 7a-hydroxylase at the gene transcription level in both species (30) . The data in this report shows that in humans the amount of available cholesterol substrate, M( 12), is excessive supporting the latter means of regulation of bile acid synthesis by hepatic cholesterol.
The reason(s) that FC in the liver exchanges extensively and rapidly with plasma HDL but not LDL or VLDL is unknown. Intimate contact between plasma lipoproteins and hepatocyte via the space of Disse offers a partial explanation. However, blood cells are even more intimately exposed to plasma and they exchange FC several-fold slower than does the liver. The unique features of hepatocyte plasma membranes could include HDL receptors, phospholipid composition, or the proximity of hepatic lipase.
The findings support a central role for HDL in FC exchange/transport and agree with evidence from Francone et al. that cell derived FC appears first in HDL (7, 31) . All tissues identifiable with our model, C(12), C(3), and C(6), exchanged FC with HDL much more extensively than with VLDL/LDL. This preferential exchange with HDL FC occurred even though the mass of HDL FC was only 25% of VLDL/LDL FC.
In 10 ofthe 12 experiments in these bile fistula subjects, the major pathway for plasma EC output was to the liver, C( 12). In the two exceptions, plasma EC output was preferentially to nonhepatic tissue, C(6). However, both of these exceptions were studied for a brief duration (< 1,000 min) and the EC pathways were poorly defined because of this. Therefore, we conclude that the major site of plasma EC uptake is the liver. This is compatible with knowledge that, quantitatively in humans, the liver is the prevailing organ with regard to LDL receptor number and LDL catabolism.
